In response to the growing opioid epidemic, HHS announced a three-pronged initiative in March 2015 to: (1) improve opioid prescribing practices; (2) increase access to naloxone for overdose management; and (3) expand medication-assisted treatment (MAT) to reduce opioid dependence.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 101 - 110 of 160. 10 per page. Page 11.
Advanced SearchCompetition and Choice in the Health Insurance Marketplaces, 2014-2015: Impact on Premiums
ASPE ISSUE BRIEF Steven Sheingold, Nguyen Nguyen, and Andre Chappel Disclaimer Persons with disabilities having problems accessing this document may call (202) 690-6870 for assistance.
Examination of Clinical Trial Costs and Barriers for Drug Development
Pharmaceutical companies conduct clinical trials for many reasons. The most obvious goal of clinical trials is to demonstrate safety and efficacy to gain Food and Drug Administration (FDA) approval. FDA provides guidance to developers about what constitutes acceptable clinical trials and appropriate outcomes.
ASPE Issue Brief, Report
Estimated Savings of $5,000 to Each Medicare Beneficiary from Enactment Through 2022 Under the Affordable Care Act
This report provides estimates of Medicare Parts A, B, and D savings from the Affordable Care Act to seniors and people living with disabilities enrolled in traditional Medicare.